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New perspectives in oral peptide
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Owing to their structural diversity, peptides are a unique source of innovative active ingredients.
However, their development has been challenging because of their disadvantageous pharmacokinetic
(PK) properties. Over the past decade, many attempts have been made to improve the oral bioavailability
of peptide drugs. In this review, we highlight the most recent and promising techniques aimed at the
improvement of the oral bioavailability of peptides. The most recent findings will influence future
approaches of pharmaceutical companies in the development of new, more efficient, and safer orally
delivered peptides.Introduction
According to Verified Market Research, the global therapeutic
peptides market was valued at US$26.98 billion in 2019 and is
projected to reach US$51.24 billion by 2027, growing at a com-
pound annual growth rate (CAGR) of 8.7% from 2020 to 2027 [1].
According to ‘Allied Market Research‘ the oral protein- and pep-
tide-based drug market accounted for $ 643 million in 2016, and is
anticipated to reach $ 8’233 million by 2028, registering a CAGR of
11.7 % from 2022 to 2028 [2].
The top-selling peptide drug for metabolic diseases is liraglutide
(Victoza1), a glucagon-like peptide (GLP-1). Popular peptide
drugs, including leuprolide (Lupron1), goserelin (Zoladex1),
the somatostatin analogs octreotide, and lanreotide, contributed
to >US$4 billion in sales. The growth in the industry will likely be
fueled by the expected increasing incidence of metabolic disorders
and cancers. Clinical trials with oral protein and peptide products
have progressively increased, culminating in September 2019,
with the US Food and Drug Administration (FDA) approval of
semaglutide (Rybelsus1) developed Novo Nordisk AG as an oral
application against type 2 diabetes mellitus (T2DM). Drugs for oral
use are dominating the therapeutic scenario, covering >50% of
FDA approvals [3]. Companies are actively developing oral peptidePlease cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide delive
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https://doi.org/10.1016/j.drudis.2021.01.020 delivery technologies and/or have in their pipelines studies of oral
peptide-targeting indications, such as cancer, diabetes, endome-
triosis, osteoporosis, bacterial infections, and others.
Nanoparticles
Nanoparticles (NPs), solid particles ranging between 1 and 100 nm
in size, define delivery systems having colloidal properties when
dispersed in an aqueous phase (e.g., liposomes, nanoemulsions,
microemulsions, microclusters, colloidosomes, and biopolymers).
In 2007, Gurny and colleagues described the improved solubility
of low-soluble compounds formulated in NPs for oral administra-
tion by using polymers such as EUDRAGIT1 L and S, and cellulose
derivatives, such as hydroxypropyl methyl cellulose acetate succi-
nate, hydroxypropyl methyl cellulose phthalate, cellulose acetate
phthalate, and cellulose acetate trimellitate [4]. Enhanced bio-
availability was also reported by Vol and colleagues, disclosing a
pharmaceutical composition comprising silica NPs with a hydro-
phobic surface, branched with polysaccharides, and a biologically
active protein or peptide embedded in an oil [5]. Following these
findings, the Oshadi Drug Administration Ltd developed an oral
carrier for insulin [5–7]. The Oshadi Icp, a combination of insulin,
proinsulin, and C-peptide insulin, was shown to be safe and
effective in lowering blood glucose [7]. Oshadi oral insulin is
currently in Phase II clinical trials (Table 1). Whether the inorganicry, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.drugdiscoverytoday.com 1
REVIEWS Drug Discovery Today Volume 00, Number 00  February 2021
DRUDIS-2911; No of Pages 9
TABLE 1
Examples of orally administrated insulin strategies
Company Name Strategy Comments Status
Biocon Ltd Insulin Tregopil PE and PEGylation Sodium caprate included as
permeability enhancer in insulin
prodrug (PEG-alkylated insulin) tablet




Oral HDV-Insulin HDV Insulin bound to HDV, the phospholipid
bilayer of which has specific HTMs






Generex Oral-lynTM Surfactants forming insulin-containing
micelles are used as absorption
enhancers; insulin delivered via
Rapidmist TM device
Phase III NCT00668850: T1DM
Novo Nordisk
Pharma AG
I338 GIPET1 Microemulsion systems based on
medium-chain fatty acid glycerides
formulated in enteric-coated tablets
Phase II NCT02470039: T2DM.
Glycemic control and safety profile
comparable to that of IGlar. Long-
term effects of sodium caprate in
intestine must be verified
– SOMA Milliposts Self-orienting ingestible device
comprising core of stainless steel and
low-density polycaprolactone that
autonomously deploys milliposts
loaded with peptide into gastric
epithelium
Preclinical studies. Milliposts of
insulin successfully delivered
showing blood glucose reduction.
Stomach delivery makes dose
delivery time more predictable.
Device recovered from feces
– LUMI microneedle Compressed spring driven by osmotic
pump propelling drug-loaded
microneedles into small intestine
Preclinical studies. No signs of
inflammation observed. Device
relies on gastric emptying to move
from stomach to small intestine
Oramed
Pharmaceuticals Inc.
ORMD-0801 PODTM EDTA, bile salts, peptidase inhibitors,
and soyabean trypsin inhibitor
incorporated with omega-3 fatty acids
into oral enteric-coated formulation
Phase II NCT00867594: T1DM;




Oshadi-Icp Oshadi carrier NP NP comprising silica core branched
with polysaccharides, and oil
combination of insulin, proinsulin, and
C-peptide
Phase II NCT01973920: T1DM;
plasma glucose lowering









EENNPs will be cleared without body accumulation is still under
investigation [8].
NPs are of interest because they promote a higher distribution of
the drug at the intestinal epithelium [9]. However, the gastroin-
testinal (GI) tract mucus can reduce NP performance as delivery
systems [10]. The mucus barrier, which has a protective function,
affects the fate of oral therapeutic peptide NPs; thus, mucus-
penetrating NPs have been developed. The addition of hydrophilic
polymers, such as polyethylene glycol (PEG), displayed enhanced
mucus penetration; insulin formulated in NPs coated with 2-
hydroxypropyl methacrylamide polymer [11,12] showed im-
proved epithelial uptake and reduced degradation compared with
nonformulated insulin [13].
Diasome Pharmaceuticals Inc. developed a novel vesicle-con-
taining insulin that is directly delivered to the liver. Hepatic-
directed vesicle insulin (HDV-I) is a NP with a diameter <150
nm and a surface modified to be able to molecularly target hepa-
tocytes (HTM) (Fig. 1). This allows uptake from the gut through the
hepatic portal vein after oral administration and protects insulin
from proteolytic degradation [14]. The oral formulation has no
free insulin and all the insulin is bound to HDV and formulated as
oral gel cap [15]. Diasome Pharmaceuticals Inc. performed clinical
trials with HDV-I for subcutaneous (s.c.) and oral administrationPlease cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide delive
2 www.drugdiscoverytoday.com[15]. Geho and colleagues observed that oral HDV-I was generally
safe and well tolerated with no incidence of hypoglycemic epi-
sodes or serious adverse events, although with a lack of linear dose
response [16]. Oral HDV-I for the treatment of T2DM is in clinical
Phase IIb trials (Table 1), with Phase III trials planned for type 1
diabetes mellitus (T1DM) with injectable HDV-I [17].
Generex Oral-lynTM is a liquid formulation of insulin delivered to
the oral cavity through the RapidMistTM device (an aerosol-type
device containing non-chlorofluorocarbon propellant, penetration
enhancers, and stabilizers). The Oral-LynTMdelivery system delivers
insulin to the oral mucosa through micelles >7 nm in size, which,
therefore,donotenterthe respiratorysystem(Fig.1).Thesurfactants
used for the micelles containing insulin were shown to behave as
permeation enhancers. The delivery device introduces a fine particle
aerosol at high velocity into the oropharyngeal cavity for local trans-
mucosal absorption [18]. In a study with patients with T1DM, Oral-
lynTM insulin was compared with insulin s.c. injections; Oral-lynTM
was shown to act more quickly compared with s.c. injections,
suggesting that buccal insulin is more reflective of a normal insulin
response to meal intake. Oral-lynTM is in Phase III clinical trials for
T1DM (Table 1) and was approved by the FDA in 2009 for treatment
of patients not eligible for Phase III clinical trials under the Investi-
gational New Drug (IND) program [19].ry, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
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FIGURE 1
Assessment of techniques involved in peptide oral bioavailability improvement: (a) Hepatic-directed vesicle (HDV) insulin containing a hepatocyte-targeting
molecule (HTM) on the nanoparticle surface. (b) Generex Oral-lynTM comprises micelles enclosing insulin and permeation enhancers, applied with a propellant
into the buccal cavity microneedle devices include (c) a RaniPillTM, a robotic pill targeting peptides into the gastrointestinal (GI) tract, (d) SOMA, targeting the
gastric epithelium and LUMI targeting the GI tract. (e) Permeation enhancers (PODTM, Eligen1, GIPET1, Peptelligence1, and TPETM) are used in peptide
formulations targeting the GI tract. (f) Self-emulsifying drug delivery systems (SEDDS) are mixtures of lipids, surfactants, and co-solvents that improve peptide
bioavailability. (g) Cyclic peptides show improved stability from enzymatic degradation and enhanced membrane permeability. (h) Peptide conjugation,














Microneedle technology has been studied over the past two dec-
ades for several medical applications, from transdermal applica-
tion, to vaccine delivery and targeting the cornea [20]. ThisPlease cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide deliveapproach has been adapted for the delivery of peptides and pro-
teins and represents a new concept to deliver molecules that
notably have low oral bioavailability [21,22]. It is crucial to under-
stand the interaction of such devices with the intestinal mucosary, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
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EENbecause these approaches can be invasive, increasing the risk of
mucosal perforation. Moreover, intestinal peristalsis is strongly
patient dependent and, therefore, PK values can show consider-





Schematic assessment of strategies involved in the oral delivery of peptides. (a) Protea
delivery of peptides. (b) Permeation enhancers are successfully used for oral delive
enable the passage of themolecule throughthemucus layer, cellmembranes,andtigh
modulate the physicochemical properties of peptides and, thus, have been applied
4 www.drugdiscoverytoday.comThe robotic pill or RaniPillTM is an enteric-coated capsule-like
tablet. A hydroxypropyl methylcellulose capsule, enteric-coated
with a polymer dissolving at a pH > 6.5, contains a balloon that,
once swallowed, remains intact inside the stomach until it reachesry, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
Drug Discovery Today 
se inhibitors, permeation enhancers, and microneedles are effective for the oral
ry, such as salcaprozate sodium (SNAC), bile salts, and sodium caprylate. They
t junctions. (c)Chemicalmodification andcyclizationaresuitable tools touse to
 for the oral delivery of peptides. Figure created with BioRender.com.
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the jejunum. Here, the shell dissolves at the higher pH under the
generation of carbon dioxide, inflating the balloon, which exposes
dissolvable sucrose-based needles that pierce the intestinal wall
and deliver the drug into the bloodstream [23] (Figs 1 and 2).
This cylindrical microneedle pill, measuring 2 cm in length and
1 cm in diameter, demonstrated its utility to deliver octreotide and
is currently in Phase I trials (Table 1) [8]. Rani Therapeutics LLC has
reported that the capsule has been safely tested in humans, report-
ing no adverse events [24]. Insulin delivery has been tested and
preclinical studies have demonstrated that the relative oral avail-
ability of insulin was almost 100% compared with s.c. application
[25]. However, the pill was manually inserted into the jejunal wall
of the anesthetized animals and, to our knowledge, no other data
are currently available; thus the performance of the pill needs to be
evaluated in clinical studies.
Self-orienting millimeter-scale applicator (SOMA) is another
oral delivery system inspired by the passive capability of the
leopard tortoise to reorient (Fig. 1). This device was developed
by Abramson and colleagues in 2019 as an ingestible device
comprising a core of stainless steel and low-density polycaprolac-
tone that autonomously deploys milliposts loaded with the pep-
tide into the gastric epithelium [26]. Milliposts of insulin were
successfully delivered in preclinical studies showing blood glucose
reduction (Table 1). The device has been recovered in feces. Such
direct stomach delivery rather than to the intestine would likely
make the dose delivery time more predictable, given the variability
in gastric emptying [27].
Luminal unfolding microneedle injectors (LUMI) are orally
dosed devices created by the same group of Abramson, which
insert drug-loaded microneedles into the small intestine wall
(Table 1 and Fig. 1) [28]. This device is enclosed into a capsule
(9  30 mm) coated with poly(methacrylic acid-co-ethyl acrylate),
able to dissolve at a pH of 5.5; a compressed spring pushes the
LUMI out of the capsule through an osmotic-controlled release
delivery system called OROS1, which has been approved by the
FDA [29]. In the GI tract, there is an established osmotic gradient,
which draws water into the capsule. The released device has three
degradable arms comprising biodegradable polyethylene oxide
(PEO) and Soluplus1 (a polyvinyl caprolactam-polyvinyl acetate
polyethylene glycol graft copolymer), which expands the tissue
wall and pushes a 1-mm patch with drug-loaded microneedles.
The arms degrade within 24 h in vitro and in vivo. The insulin
loaded device showed a systemic bioavailability higher than 10%
compared to that observed with a s.c. injection [28].
The effect of prolonged use of these devices should be evaluated
in long-term studies to understand the effects of microneedles on
the intestinal mucosa. Moreover, to reach the intestine wall, the
LUMI device relies on gastric emptying, which typically occurs in
1–4 h but can take up to 24 h in individuals with gastroparesis, as
observed in patients with diabetes [27,30]. Thus, this factor could
be cause of delay or uncertainty in the PK of this device.
Permeation enhancers
Oramed Pharmaceuticals Inc. developed Protein Oral Delivery
(PODTM). This is a system where different strategies coexist in
the same formulation: encapsulation, permeation enhancers, a
chelating agent, and a protease inhibitor. Oramed’s technology is
based on components aimed at providing protection duringPlease cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide delivepassage through the GI tract and enhancing absorption. Ethylene-
diaminetetraacetate sodium (EDTA) and bile salts act as perme-
ation enhancers. The capsule protects insulin from hydrolysis in
the stomach, whereas protease inhibitors, such as soybean trypsin
inhibitor and aprotinin, protect insulin from protease degrada-
tion, especially in the small intestine (Fig. 2) [31].
Insulin has been formulated with the Oramed technology,
showing decreased postprandial glucose levels in patients with
T1DM and in fasting patients with T2DM. Phase II clinical results
from trials with patients with T1DM showed good tolerability. A
completed Phase IIb trial also showed a significant lowering of
mean night-time glucose levels in adults with T2DM (Table 1) [32].
The relevance of some surfactants and medium-chain fatty acids
(MCFAs) as absorption enhancers is particularly relevant in such
formations [33]. Fatty acids are nutrients released during the
digestion of glycerides in the GI tract. The most extensively
studied MCFA is sodium caprate, a salt of capric acid, which
comprises 2–3% of fatty acids in the milk fat fraction. Several
compounds have been investigated for oral delivery of peptides: N-
(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) [34], 4-([4-
chloro-2-hydroxybenzoyl]-amino) butanoic acid (4-CNAB) [35],
and N-(8-[2-hydroxybenzoyl]-amino) caprylic acid, also known
as salcaprozate sodium (SNAC) (Fig. 2).
Emisphere Technologies used SNAC as permeation enhancer for
poorly intestinally permeable compounds (Fig. 1) [36]. SNAC, also
known as Eligen1, is generally regarded as safe and was used to
develop an oral vitamin B12. SNAC also resulted in improved oral
bioavailability of insulin [35] and calcitonin [37], showing no
toxicity and no impact on tight junctions [38]. Semaglutide, a
glucagon-like peptide-1 (GLP-1) analog, has been co-formulated
with the Eligen1 technology as a tablet for oral administration.
Semaglutide, a glucagon-like peptide-1 (GLP-1) analog, has been
co-formulated with the Eligen1 technology as a tablet for oral
administration, showing to be well tolerated in subjects with
varying degrees of renal impairments [39]. The Novo Nordisk
clinical trial PIONEERs showed efficacy and safety in patients with
T2DM and moderate renal impairment in a clinical trial Phase IIIa
consistent with results for the GLP-1 receptor agonist (Table 2)
[40]. The first oral GLP1 receptor agonist, semaglutide, using the
Eligen1 technology, was approved by the FDA in 2019 for the
treatment of T2DM. Concerning the mechanism of action, many
hypotheses have been provided. It is uncertain whether the SNAC
permeation improvement results from membrane perturbation,
solubility modulation, or tight junction opening, or whether it
improves transcellular permeation (Fig. 2). However, the hypoth-
esis of membrane perturbation was excluded by Novo Nordisk AG,
who argued that SNAC creates a complex with semaglutide in the
stomach, protecting the drug from pepsin and increasing the
concentration-dependent flux of semaglutide through the gastric
mucosa [41].
Merrion Pharmaceuticals Plc. developed GIPET1 technology
(Gastrointestinal Permeation Enhancement Technology).
GIPET1 comprises a sodium salt of capric acid, a soluble anionic
surfactant, delivered in an enteric-coated solid dosage form. The
first format of GIPET1 (GIPET I) comprised enteric-coated tablets
with a pH-sensitive coating (e.g., Eudragit1), a medium-chain
fatty acid (e.g., C10) and a drug in selected ratios. The last modifi-
cation of the technology (GIPET II) was an emulsion of mono- andry, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
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TABLE 2
Examples of orally administrated peptide drugs
Strategy Comments Name Company Status
Chemical modification
cyclization
Generation of peptide bond
between original N- and C- termini
to overcome poor intestinal stability
of linear peptides
Desmopressin, DDAVP1 Ferring Pharmaceuticals SA Marketed. Indicated for diabetes
insipidus, hemophilia A, von
Willebrand disease, and high blood
urea levels
Voclosporin Aurinia Pharmaceuticals Inc. Phase III NCT03597464 AURORA2:
active against lupus nephritis,
uveitis
Nepadutant Menarini Pharma AG Phase II NCT01258153NO-CRY:
infant colic
LFF571 Novartis Pharma AG Phase II NCT01232595: Clostridium
difficile infection
TPETM Oily suspension formulated from
sodium caprylate, PVP forming a
hydrophilic powder suspended in
lipophilic medium of glyceryl
mono- and tricaprylate
Octreotide, Mycappsa1 Chiasma Inc. Phase III NCT03252353: acromegaly
Microneedle In enteric-coated capsule,
generation of carbon dioxide
inflates a small balloon that pushes
out sucrose-based needles
Octreotide Rani Therapeutics LLC Phase I NCT03798912: acromegaly




Salmon calcitonin, TBRIATM Tarsa Therapeutics Inc. Phase II NCT00959764 ORACAL:
postmenopausal osteoporosis
Leuprolide, Ovarest1 Enteris BioPharma Inc. Phase II NCT02807363:
endometriosis
Difelikalin, KORSUVATM Cara Therapeutics Inc. Phase II rec. NCT04018027 KARE:
pruritus, atopic dermatitis
Eligen1, Emisphere SNAC as absorption enhancer in
tablets with 3, 7, or 14 mg
semaglutide
Semaglutide Rybelsus1 Novo Nordisk Pharma AG Phase III NCT03015220 PIONEER 10:
T2DM
SEDDS Lipid-based microemulsion




Novartis Pharma AG Marketed. Prevention of transplant
rejection, treatment of patients with








EENdiglyceride mixtures of C8 and C10 with the drug enclosed in an
enteric-coated soft gel capsule (Figs 1 and 2). GIPET1 has been
used with alendronate and desmopressin to improve oral bioavail-
ability in humans compared with unformulated controls [42].
Novo Nordisk insulin formulated with GIPET1, I338, is in Phase
II clinical trials (Table 1). I338 was recently compared against
subcutaneous insulin (iGlar), a well-established basal insulin treat-
ment in patients with T2DM. The clinical trial Phase II study,
completed in 2019, showed that oral insulin provided glycemic
control not significantly different from that of iGlar over 8 weeks
of once-daily treatment, and that the two products had a similar
safety profile. The higher glycemic variability with I338 could
increase the risk of hypoglycemia and the effects of the high
concentration of sodium caprate in the intestine remain to be
verified. Nevertheless, these results encourage the development of
oral insulin products and strengthen the aspiration to make oral
insulin available to patients with diabetes [43].
Peptelligence1 technology is able to enhance paracellular
transport in the intestine; the peptides are delivered in an enter-
ic-coated tablet where the core comprises lyophilized peptide,
maltodextrin-coated citric acid, and acylcarnitine [44,45]. Salmon
calcitonin, TBRIATM, Leuprolide, Ovarest1, and Difelikalin, KOR-
SUVATM have been formulated with Peptelligence1 and are inPlease cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide delive
6 www.drugdiscoverytoday.comPhase II trials. (Table 2). In the ORACAL trial, salmon calcitonin
was evaluated for its efficacy and safety in women with postmen-
opausal osteoporosis: an improvement in the mineralization of
spinal bone superior to that obtained with commercial nasal
salmon calcitonin spray was observed, although adverse GI effects
led to premature Phase III withdrawal [46].
Transient Permeability Enhancer, TPETM, developed by Chias-
ma Inc., and comprises a combination of excipients including
sodium caprylate, in which the hydrophilic powder containing
the active pharmaceutical ingredient is suspended, creating an oily
suspension. (Fig. 1) [47]. Mycapssa1, developed by Chiasma Inc.,
is an oral octreotide capsule formulated with TPETM [48]. In vivo
studies with octreotide, sodium caprylate, and fluorescein isothio-
cyanate (FITC)-labeled dextran showed permeation enhancement
and reorganization of the tight junction proteins ZO-1 and clau-
din-3 [47]. The sodium caprylate excipient has a crucial role in
permeation enhancement enabling transient and reversible para-
cellular tight junction passage of molecules (Fig. 2) [49], although
the mechanism is not fully elucidated. The oral octreotide formu-
lation was tested for efficacy and safety in a clinical trial Phase III in
patients with acromegaly, showing to be effective and safe as an
acromegaly monotherapy (Table 2). This study proved that
daily oral administration of octreotide formulated with TPETMry, Drug Discov Today (2021), https://doi.org/10.1016/j.drudis.2021.01.020
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resulted in plasma drug levels comparable to those with octreotide
injection [50].
Self-emulsifying drug delivery systems
Self-emulsifying drug delivery systems (SEDDS) are systems com-
prising mixtures of lipids, surfactants, and co-solvents. When
dispersed in GI fluids, they form emulsions or microemulsions
(Fig. 1). These systems received increased focus in recent years
because of their ability to improve oral peptide delivery. They can
help to overcome absorption barriers by providing protection
against metabolism and improving permeation through the
intestinal mucus layer; they can also be produced in a simple
and cost-effective manner [51,52].
The only marketed peptide formulated with SEEDS is cyclospor-
in A (CsA; Sandimmune/Neoral1 produced by Novartis AG),
(Table 2). It is a microemulsion lipid-based formulation, leading
to a bioavailability of 20–40% [53]. To improve absorption of
the standard oral oil-based formulation of CsA, the lipid-based
formulation Neoral1 was developed. This new formulation is a
microemulsion preconcentrate, which, in contact with GI fluids,
forms a homogeneous, monophasic microemulsion, improving
absorption and increasing the stability of the product [54].
Advanced SEDDS can include muco-inert compounds and cell-
penetrating peptides contributing to create nanoemulsions with
increased stability in GI fluids, improved mucus-permeating prop-
erties, and enhanced permeation (Fig. 2), resulting in the increased
bioavailability of the incorporated peptides. A mucus-permeating
SEDDS formulation for oral insulin delivery contains a hydropho-
bic ion pair (HIP) of insulin/dimyristoyl phosphatidylglycerol
(INS/DMPG). More specifically, oil-surfactant–co-surfactant com-
binations were examined, and it was shown that the use of an
increased amount of Labrafil1 M1944CS (a long-chain triglycer-
ide) in combination with Transcutol1P led to enhanced mucus
permeability and high encapsulation efficiencies for insulin
(i.e., up to 70%) [55]. In vivo studies with SEDDS with HIP of
peptides have been carried out, displaying promising results; for
example, exenatide was coupled with sodium docusate and incor-
porated into a SEDDS to increase mucus permeation [56].
Cyclic peptides
A successful strategy to overcome poor intestinal stability of
linear peptides is peptide cyclization (Fig. 1). The beneficial
properties of cyclic peptides are represented on the market by
CsA, a natural cyclic peptide product formulated as a microemul-
sion (Neoral1), and desmopressin, an analog of the natural
hormone vasopressin.
CsA is approved as an immunosuppressant and is available in
two preparations, cyclosporine soft gelatin capsules and cyclospor-
ine oral solution, which have been prescribed extensively as
treatments following kidney, liver, and heart transplantations.
Desmopressin, a modified analog of vasopressin, was developed
in tablet form for the treatment of diabetes insipidus during the
1980s and it is additionally administrated for primary nocturnal
enuresis. It shows greater antidiuretic activity than native vaso-
pressin, and little vasoconstrictive activity. Desmopressin also has
a prolonged antidiuretic action relative to native vasopressin, in
part because of its resistance to degradation by vasopressinase
(Table 2) [57].Please cite this article in press as: Zizzari, A.T. et al. New perspectives in oral peptide deliveCyclic peptide candidates are also in clinical drug develop-
ment. Voclosporin, a stabilized analogue of CsA (Aurinia Phar-
maceuticals Inc.), has successfully completed Phase III clinical
studies with an indication for the treatment of lupus nephritis
(Table 2 and Fig. 2) [58]. Moreover, nepadutant is a glycosylated
bicyclic hexapeptide antagonist of the receptor tachykinin NK2,
designed by the Menarini Pharma AG group. Phase II clinical
trials have been conducted on children with functional GI
disorders (Fig. 2) [59]. Additionally, Phase II human trials of
Novartis’ LFF571 (Table 2 and Fig. 2), an oral semisynthetic
thiopeptide antibiotic to treat Clostridium difficile infections, have
been completed [60]. In these trials, the safety and efficacy of
LFF571 were compared with those of vancomycin using adults
with primary episodes or first recurrences of moderate C. difficile
infection. Based on the results, the rate of clinical cure for LFF571
(90.6%) was higher compared with vancomycin (78.3%). In
addition, the recurrence rates were lower for LFF571 compared
with vancomycin [61]. However, the relevance of peptide cyclisa-
tion as a generalized strategy for the improvement of oral avail-
ability is still under investigation. Nielsen et al. examined the
physicochemical parameters and oral absorption of 125 cyclic
peptides; although most of them were small, they showed poor
oral bioavailability [62].
Peptide conjugation
A synthetic strategy that allows for the modulation of PK proper-
ties of therapeutic peptides is conjugation with moieties that
extend half-life or improve solubility. Lipidization, where the
peptide is linked with a fatty acid moiety, as well as PEGylation,
are two successful approaches (Fig. 1). Insulin Tregopil (Biocon Lt.)
is a novel PEGylated insulin analog modified for oral delivery. A
single short-chain amphiphilic oligomer attached to the Lys-b29
residue of recombinant human insulin via an amide linkage
increases the water solubility of the insulin analog. The alkylated
PEG also provides improved stability against enzymatic degrada-
tion [63–65]. Insulin Tregopil has an additional sodium caprate
excipient, a permeation enhancer, for further enhancement of
absorption in the stomach [66]. An open-label Phase II/III study to
evaluate the efficacy and safety of Insulin Tregopil in patients with
T2DM was completed in February 2019, (Table 1). However, the
results of this study have not yet been published.
Concluding remarks
There are many challenges to overcome when dealing with the
oral delivery of peptides. The development of orally delivered
peptides to replace injections remains a challenge, which would
not only help improve the lives of patients, but also reduce
healthcare costs worldwide. Orally delivered insulin is an ex-
ample of this ultimate objective, providing undisputed thera-
peutic advantages for non-invasive chronic use. However, the
improvement of life quality and the safety of patients must be
the driving force of oral delivery peptide research. The solution
to such a complex problem requires approaches from various
disciplines, with formulation and chemical modification being
vital.
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